Live Topical Biotherapeutics for the Treatment of Inflammatory Skin Disorders

An evolutionary approach to restoring health

AOBiome Therapeutics is a late stage therapeutics company addressing a broad range of inflammatory skin conditions by harnessing a single strain of class defining Ammonia Oxidizing Bacteria (AOB), whose presence on the skin has been eliminated through modern living.

RESTORING IMMUNE FUNCTIONALITY

Ammonia Oxidizing Bacteria may serve to restore proper immune response through the down regulation of IL-4, IL-5, IL-13 and IL-31. Such markers are associated with inappropriate inflammatory response in several diseases including the pruritus (itch) pathway.

AOBiome currently has multiple
Phase 2 clinical programs

AOBiome currently has Phase 2 clinical programs in acne, eczema and rosacea.

Learn More

Committed to transforming & improving human health

We believe that the restoration of the symbiotic relationship between bacteria and humans
will have a profound impact on human health.

Clinical Trials

Science

Manufacturing

About

In the News

November 16, 2021 · Cambridge, MA

AOBiome Achieves Landmark Recruitment Goal in Largest Clinical Trial Ever Powered by a Live Topical Biotherapeutic

August 17, 2021 · Cambridge, MA

AOBiome’s 30 Patient Study Using New Shelf-Stable Formulation of Its Ammonia Oxidizing Bacteria (AOB) Shows Significant Reduction of Itch Levels In Both Pediatric And Adult Subjects Who Suffer From Eczema

July 17, 2021 · Cambridge, MA

Nature Scientific Reports has published a peer reviewed paper showing important immune response benefits associated with AOBiome’s B244 Ammonia Oxidizing Bacteria drug therapy